Strategic modifications including D-amino acid substitutions and cyclization improved oxytocin's stability in the colon by up to 79% and enhanced tissue permeability, enabling potential oral peptide delivery for bowel diseases.
+79.1% colonic stabilityThree D-amino acid substitutions in cyclic oxytocin improved stability in a human colon model by 79.1% compared to native oxytocin
What the researchers found
Among 11 oxytocin-based peptide modifications tested:
- Native oxytocin's disulfide bond cyclization provided improved stability in a human colon model compared to a linear derivative
- Chloroacetyl cyclization increased stability at 1.5h by 30.0%
- Three D-amino acid substitutions (at Tyr, Ile, Leu) improved stability by 58.2% in linear and 79.1% in cyclic structures
- Thioether and N-terminal acetylated cyclizations offered no additional protection
- Three D-AA substitutions in cyclic oxytocin significantly increased permeability across rat colonic tissue, likely by favorably altering secondary structure
- The site and number of D-AA substitutions were critical for stability
Why it matters
Nearly all peptide drugs require injection because they can't survive digestion. For conditions like inflammatory bowel disease and colorectal cancer, oral delivery that targets the colon would be ideal — getting the drug directly where it's needed. This study provides a blueprint for designing peptides that can withstand the colonic environment and cross intestinal tissue, potentially enabling oral peptide therapies for gut diseases.
How the study worked
Researchers synthesized native oxytocin and 11 structural analogs with various cyclization modifications (disulfide, chloroacetyl, thioether, N-terminal acetylated) and D-amino acid substitutions. Stability was tested in a human colon model measuring enzymatic degradation. Tissue permeability was assessed using ex vivo rat colonic tissue. Structural changes were analyzed to understand how modifications affected peptide properties.
What this study cannot tell us
Oxytocin was used as a model peptide, and results may not directly translate to other therapeutic peptides with different structures and properties. Colonic stability was measured in an ex vivo model, not in vivo with full physiological conditions. Tissue permeability was assessed in rat colon, which may differ from human colon. The modifications that improved stability and permeability may alter the peptide's biological activity, which was not assessed. Formulation strategies for colon-targeted oral delivery were not included.
How to read the evidence
This is a pharmaceutical science study using ex vivo models published in Pharmaceutics. The systematic comparison of 12 peptide variants provides robust structure-activity data, though all findings are in laboratory models without in vivo or clinical validation.
When this study was published
Published in 2023, this is a recent contribution to the rapidly advancing field of oral peptide drug delivery, representing the first study focused specifically on colonic peptide design.
The bigger picture
Oral peptide delivery is one of the holy grails of pharmaceutical science. While most work has focused on stomach and small intestine survival, the colon presents unique opportunities for treating local diseases. This study opens a new avenue: designing peptides specifically for colonic stability and permeability. Combined with colon-targeted oral formulations, this could enable a new generation of oral peptide drugs for IBD, colorectal cancer, and potentially systemic diseases.
Questions still open
- Do the D-amino acid substitutions that improve stability and permeability affect the biological activity of the modified peptides?
- Can these design principles be applied to therapeutic peptides for IBD (e.g., VIP, alpha-MSH) to create oral formulations?
- What oral formulation strategies would best deliver these modified peptides specifically to the colon?
Common questions
Why can't most peptide drugs be taken as pills?
What are D-amino acids and why do they help peptides survive?
Read the original research
Impact of Peptide Structure on Colonic Stability and Tissue Permeability.
Pharmaceutics, 15(7)
Citation
Taherali, Farhan; Chouhan, Nerisha; Wang, Fanjin; Lavielle, Sebastien; Baran, Maryana; McCoubrey, Laura E; Basit, Abdul W; Yadav, Vipul. (2023). Impact of Peptide Structure on Colonic Stability and Tissue Permeability.. Pharmaceutics, 15(7). https://doi.org/10.3390/pharmaceutics15071956